Document is current
Any future updates will be listed below
-
Authors
Morgan, Duncan M. https://orcid.org/0000-0002-3253-1362
Zhang, Yiming J. https://orcid.org/0000-0002-8102-3815
Kim, Jin-Hwan
Murillo, MaryAnn
Singh, Suddham
Loschko, Jakob
Surendran, Naveen
Sekulovic, Ognjen
Feng, Ellie https://orcid.org/0009-0002-4900-4814
Shi, Shuting
Irvine, Darrell J. https://orcid.org/0000-0002-8637-1405
Patil, Sarita U.
Kanevsky, Isis
Chorro, Laurent
Christopher Love, J. https://orcid.org/0000-0003-0921-3144
-
Funding
Funding for this research was provided by:
National Cancer Center (P30-CA14051)
Pfizer
- License Information
-
More Information
Article History
Received: 13 June 2023
Accepted: 2 September 2024
First Online: 28 September 2024
Competing interests
: The authors declare the following competing interests: J.C.L. has interests in Sunflower Therapeutics PBC, Honeycomb Biotechnologies, OneCyte Biotechnologies, SQZ Biotech, Alloy Therapeutics, QuantumCyte, Amgen, and Repligen (these interests are reviewed and managed under Massachusetts Institute of Technology’s policies for potential conflicts of interest); in addition, he receives sponsored research support at Massachusetts Institute of Technology from Amgen, the Bill and Melinda Gates Foundation, Biogen, Pfizer, Sartorius, Mott Corp, TurtleTree, Takeda, and Sanofi, and his spouse is an employee of Sunflower Therapeutics PBC. J.K., M.M., S.S., L.J., N.S., I.K., and L.C. are employees of Pfizer and may, as a consequence, be shareholders. Pfizer was involved in the design, analysis, and interpretation of the data in this research study, the writing of this report, and the decision to publish. SUP consults for Mabylon and Buhlmann and conducts a clinical trial for Regeneron. The other authors declare no competing interests.
